GlassScriptPhysician profile
Stanley M Ireland
NPI 1023095536
$9,008.86
in general payments reported to CMS, 2019-2025
47 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $1,272 · 2021: $2,350 · 2022: $2,207 · 2023: $1,212 · 2024: $203 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.79 | 2020-2025 | |
| Novo Nordisk INC | $900.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $675.65 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $624.91 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $549.10 | 2019-2023 | |
| Astellas Pharma US INC | $547.66 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $497.65 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $396.32 | 2021 | |
| Abbott Laboratories | $357.10 | 2019-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.42 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.42 | 2019-2023 | Xifaxan, Trulance |
| Lilly USA, LLC | $272.42 | 2019-2025 | Mounjaro, Jardiance |
| Amarin Pharma, INC. | $215.18 | 2019-2022 | |
| Esperion Therapeutics, INC. | $208.48 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.39 | 2021-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Ireland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.